Reuters logo
Vical licenses technology, vaccine booster to Bristol-Myers; shares up
September 13, 2012 / 8:16 PM / in 5 years

Vical licenses technology, vaccine booster to Bristol-Myers; shares up

(Reuters) - Vical Inc (VICL.O) licensed its DNA immunization technology platform and its vaccine adjuvant to Bristol-Myers Squibb Co (BMY.N), sending its shares up as much as 14 percent before the bell.

Under the non-exclusive, global license, Bristol-Myers will use Vical’s technology to discover antibodies.

Vical will also supply its product Vaxfectin, an adjuvant which has been proven to improve immune response to vaccines, to Bristol-Myers from time to time.

Financial terms of the deal were not disclosed. San Diego-based Vical had cash and investments of about $97 million as of June 30, 2012.

The company’s shares, which have lost about 15 percent of their value this year, were up 14 percent at $4.30 in trading before the bell on Thursday.

Reporting by Vidya P L Nathan; Editing by Sreejiraj Eluvangal

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below